Literature DB >> 8220916

Mediation by B1 and B2 receptors of vasodepressor responses to intravenously administered kinins in anaesthetized dogs.

N Nakhostine1, C Ribuot, D Lamontagne, R Nadeau, R Couture.   

Abstract

1. Vasodepressor responses to intravenous (i.v.) injection of bradykinin (BK) and des-Arg9-BK, a selective B1 kinin receptor agonist, were characterized following i.v. pretreatment with selective B1 ([Leu8]-des-Arg9-BK) and B2 (Hoe 140) kinin receptor antagonists in anaesthetized dogs. 2. Des-Arg9-BK (0.05-3.3 nmol kg-1) produced dose-dependent decreases in mean arterial blood pressure with a ED50 0.4 nmol kg-1. The vasodepressor effects evoked by des-Arg9-BK (0.6 nmol kg-1) and BK (0.2 nmol kg-1) were greater after i.v. and i.a. injections, respectively. 3. The vasodepressor response to BK (0.6 nmol kg-1) but not to des-Arg9-BK (0.6 nmol kg-1) was significantly (P < 0.001) blocked by pretreatment with the B2 receptor antagonist, Hoe 140. 4. The vasodepressor response to des-Arg9-BK (0.6 nmol kg-1) but not to BK (0.6 nmol kg-1) was significantly (P < 0.001) reduced by pretreatment with the selective B1 receptor antagonist, [Leu8]-des-Arg9-BK. Although both B1 and B2 receptor antagonists caused a transient fall in blood pressure, their inhibitory action was unlikely to be related to a desensitization mechanism. 5. Inhibition of prostaglandin synthesis with indomethacin prevented the vasodepressor response induced by arachidonic acid (1 mg kg-1, i.v.) but not that to BK or des-Arg9-BK (0.6 nmol kg-1). 6. These results suggest, firstly, that the vasodepressor responses to i.v. BK and des-Arg9-BK are mediated by the activation of B2 and B1 receptors, respectively; secondly, that prostaglandins are not involved in the vasodepressor responses to kinins.These findings provide pharmacological evidence for the existence of functionally active B1 receptors in canine cardiovascular homeostasis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8220916      PMCID: PMC2175980          DOI: 10.1111/j.1476-5381.1993.tb13773.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  17 in total

Review 1.  Pharmacology of kinins: their relevance to tissue injury and inflammation.

Authors:  F Marceau; A Lussier; D Regoli; J P Giroud
Journal:  Gen Pharmacol       Date:  1983

2.  Peptides and the human colon: an in vitro pharmacological study.

Authors:  R Couture; J Mizrahi; D Regoli; G Devroede
Journal:  Can J Physiol Pharmacol       Date:  1981-09       Impact factor: 2.273

Review 3.  Pharmacology of bradykinin and related kinins.

Authors:  D Regoli; J Barabé
Journal:  Pharmacol Rev       Date:  1980-03       Impact factor: 25.468

4.  New, long-acting, potent bradykinin antagonists.

Authors:  F Lembeck; T Griesbacher; M Eckhardt; S Henke; G Breipohl; J Knolle
Journal:  Br J Pharmacol       Date:  1991-02       Impact factor: 8.739

5.  Receptors for kinins in isolated arterial vessels of dogs.

Authors:  N E Rhaleb; S Dion; J Barabé; N Rouissi; D Jukic; G Drapeau; D Regoli
Journal:  Eur J Pharmacol       Date:  1989-03-29       Impact factor: 4.432

6.  Pharmacological characterization of a new highly potent B2 receptor antagonist (HOE 140: D-Arg-[Hyp3,Thi5,D-Tic7,Qic8]bradykinin).

Authors:  N E Rhaleb; N Rouissi; D Jukic; D Regoli; S Henke; G Breipohl; J Knolle
Journal:  Eur J Pharmacol       Date:  1992-01-14       Impact factor: 4.432

7.  Induction of beta 1-receptors for kinins in the rabbit by a bacterial lipopolysaccharide.

Authors:  D C Regoli; F Marceau; J Lavigne
Journal:  Eur J Pharmacol       Date:  1981-04-24       Impact factor: 4.432

8.  Studies on the induction of pharmacological responses to des-Arg9-bradykinin in vitro and in vivo.

Authors:  J Bouthillier; D Deblois; F Marceau
Journal:  Br J Pharmacol       Date:  1987-10       Impact factor: 8.739

9.  Cardiovascular actions of kinins in the rabbit.

Authors:  J Barabé; F Marceau; B Thériault; J N Drouin; D Regoli
Journal:  Can J Physiol Pharmacol       Date:  1979-01       Impact factor: 2.273

10.  Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies.

Authors:  F J Hock; K Wirth; U Albus; W Linz; H J Gerhards; G Wiemer; S Henke; G Breipohl; W König; J Knolle
Journal:  Br J Pharmacol       Date:  1991-03       Impact factor: 8.739

View more
  5 in total

Review 1.  Development biology of the renal kallikrein-kinin system.

Authors:  S S el-Dahr
Journal:  Pediatr Nephrol       Date:  1994-10       Impact factor: 3.714

2.  Effect of enalaprilat on bradykinin and des-Arg9-bradykinin release following reperfusion of the ischaemic rat heart.

Authors:  D Lamontagne; R Nadeau; A Adam
Journal:  Br J Pharmacol       Date:  1995-06       Impact factor: 8.739

3.  Modulatory effect of bradykinin on the release of noradrenaline from rat isolated atria.

Authors:  C Chulak; R Couture; S Foucart
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

4.  Up-regulation of kinin B1 receptor in the lung of streptozotocin-diabetic rat: autoradiographic and functional evidence.

Authors:  Rose Mari J Vianna; Brice Ongali; Domenico Regoli; João Batista Calixto; Réjean Couture
Journal:  Br J Pharmacol       Date:  2003-01       Impact factor: 8.739

5.  Haemodynamic and cardiac effects of kinin B1 and B2 receptor stimulation in conscious instrumented dogs.

Authors:  P Bélichard; B Loillier; J L Paquet; J M Luccarini; D Pruneau
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.